Safety and Immunogenicity of Anti-SARS-CoV-2 Booster Dose in Patients with Chronic Liver Disease
The low response to vaccines is a well-known problem in cirrhosis. We evaluated the safety and immunogenicity of booster doses in patients with chronic liver disease (CLD), comparing the humoral response in cirrhotic vs. non-cirrhotic patients, and the impact of different factors on immune response....
Main Authors: | Valentina Cossiga, Mario Capasso, Maria Guarino, Ilaria Loperto, Stefano Brusa, Francesco Maria Cutolo, Maria Rosaria Attanasio, Raffaele Lieto, Giuseppe Portella, Filomena Morisco |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-03-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/12/6/2281 |
Similar Items
-
COVID-19 and Fatty Liver Disorders
by: Maria Guarino, et al.
Published: (2023-06-01) -
Relevance of Bile Acids in Cholangiocarcinoma Pathogenesis: Critical Revision and Future Directions
by: Valentina Cossiga, et al.
Published: (2023-06-01) -
Gender and Autoimmune Liver Diseases: Relevant Aspects in Clinical Practice
by: Federica Invernizzi, et al.
Published: (2022-06-01) -
Use of Telemedicine for Chronic Liver Disease at a Single Care Center During the COVID-19 Pandemic: Prospective Observational Study
by: Guarino, Maria, et al.
Published: (2020-09-01) -
Enhanced liver fibrosis score as a noninvasive biomarker in hepatitis C virus patients after direct-acting antiviral agents
by: Valentina Cossiga, et al.
Published: (2022-08-01)